Quantitative analysis of Survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer

Journal of Surgical Oncology

Volumn 100, Issue 6, 2009, Pages 447-451

  Grimminger, Peter ^a   Vallböhmer, Daniel ^a   Hoffmann, Andreas ^a   Schulte, Christian ^a   Bollschweiler, Elfriede ^a   Schneider, Paul M ^b   Hölscher, Arnulf H ^a   Metzger, Ralf ^a   Brabender, Jan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Esophageal cancer; Response prediction; RNA expression; Survivin

Indexed keywords

BETA ACTIN; CISPLATIN; FLUOROURACIL; SURVIVIN;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MALE; NON INVASIVE MEASUREMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ACTINS; ADENOCARCINOMA; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODE EXCISION; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOADJUVANT THERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 70350341513     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21355     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Whooley BP, Law S, Murthy SC, et al.: Analysis of reduced death and complication rates after esophageal resection. Ann Surg 2001;233:338-344. (Pubitemid 32187811)
3. Ando N, Ozawa S, Kitagawa Y, et al.: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225-232. (Pubitemid 30616724)
4. Refaely Y, Krasna MJ: Multimodality therapy for esophageal cancer. Surg Clin North Am 2002;82:729-746.
5. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467. (Pubitemid 26269945)
6. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313. (Pubitemid 32112841)
7. Schneider PM, Baldus SE, Metzger R, et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 2005;242:684-692. (Pubitemid 41567124)
8. Hisamitsu K, Fukuda K, Oka S, et al.: Immunohistochemical study of dihydropyrimidine dehydrogenase (DPD) and p53 in biopsied specimens of esophageal cancer before chemoradiotherapy. Gan To Kagaku Ryoho 2001;28:1527-1529.
9. Joshi MB, Shirota Y, Danenberg KD, et al.: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-2221.
10. Langer R, Specht K, Becker K, et al.: Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005;11:7462-7469. (Pubitemid 41507707)
11. Langer R, Specht K, Becker K, et al.: Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy. Am J Clin Pathol 2007;128:191-197. (Pubitemid 47262616)
12. Ling FC, Leimbach N, Baldus SE, et al.: HIF-1alpha mRNA is not associated with histopathological regression following neoadjuvant chemoradiation in esophageal cancer. Anticancer Res 2006;26:4505-4509. (Pubitemid 46031524)
13. Miyazono F, Metzger R, Warnecke-Eberz U, et al.: Quantitative cerbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004;91:666-672. (Pubitemid 39141621)
14. Schneider S, Uchida K, Brabender J, et al.: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005;200:336-344. (Pubitemid 40298967)
15. Theisen J, Danenberg K, Ott K, et al.: Predictors of response and survival for neoadjuvant treated patients with esophageal adenocarcinoma. Dis Esophagus 2008;21:601-606.
16. Vallbohmer D, Kuhn E, Warnecke-Eberz U, et al.: Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 2008;9:681-690.
17. Warnecke-Eberz U, Hokita S, Xi H, et al.: Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13:1241-1246. (Pubitemid 41746946)
18. Warnecke-Eberz U, Metzger R, Miyazono F, et al.: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10:3794-3799. (Pubitemid 38697614)
19. Xi H, Baldus SE, Warnecke-Eberz U, et al.: High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005;11:8341-8347. (Pubitemid 41746946)
20. Hoffmann AC, Warnecke-Eberz U, Luebke T, et al.: Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol 2007;95:51-54. (Pubitemid 46122718)
21. Brabender J, Vallböhmer D, Grimminger G, et al.: ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg 2008;12:1815-1821.
22. Li F, Ambrosini G, Chu EY, et al.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584. (Pubitemid 28563719)
23. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921. (Pubitemid 27353455)
24. Nemoto T, Kitagawa M, Hasegawa M, et al.: Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 2004;76:253-259. (Pubitemid 38569787)
25. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, et al.: Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003;88:115-119. (Pubitemid 36241227)
26. Kato J, Kuwabara Y, Mitani M, et al.: Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-95. (Pubitemid 32187079)
27. Gibson UE, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001. (Pubitemid 26388092)
28. Heid CA, Stevens J, Livak KJ, et al.: Real time quantitative PCR. Genome Res 1996;6:986-994.
29. Metz CE, Goodenough DJ, Rossmann K: Evaluation of receiver operating characteristic curve data in terms of information theory, with applications in radiography. Radiology 1973;109:297-303.
30. Fortugno P, Wall NR, Giodini A, et al.: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-585. (Pubitemid 34182984)
31. Brabender J, Lord RV, Danenberg KD, et al.: Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Gastrointest Surg 2001;5:174-181, discussion 182. (Pubitemid 33652057)
32. Brabender J, Lord RV, Metzger R, et al.: Role of retinoid X receptor mRNA expression in Barrett's esophagus. J Gastrointest Surg 2004;8:413-422. (Pubitemid 38561204)
33. Brabender J, Lord RV, Wickramasinghe K, et al.: Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg 2002;6:359-367. (Pubitemid 40433540)
34. Brabender J, Marjoram P, Lord RV, et al.: The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005;14:2113-2117. (Pubitemid 41603254)
35. Brabender J, Marjoram P, Salonga D, et al.: A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene 2004;23:4780-4788. (Pubitemid 38859466)
36. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-968.
37. Banki F, Mason RJ, Oh D, et al.: Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch Surg 2007;142:533-538, discussion 538-539. (Pubitemid 46956399)
38. Fiegl H, Millinger S, Mueller-Holzner E, et al.: Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65:1141-1145. (Pubitemid 40270136)
39. Sherman CA, Turrisi AT, Wallace MB, et al.: Locally advanced esophageal cancer. Curr Treat Options Oncol 2002;3:475-485.